Novavax Inc. said its two-dose Covid-19 vaccine demonstrated “strong immune responses” against the Omicron variant and other variants of the coronavirus, citing initial data.
Still, the company said neutralization against the Omicron variant was “4-fold lower” than it was against the original strain of the virus, suggesting that a booster shot or a new Omicron-specific vaccine would be beneficial.